IL308020A - Combination of anti-galectin-9 antibodies and chemotherapeutic agents for use in cancer treatment - Google Patents
Combination of anti-galectin-9 antibodies and chemotherapeutic agents for use in cancer treatmentInfo
- Publication number
- IL308020A IL308020A IL308020A IL30802023A IL308020A IL 308020 A IL308020 A IL 308020A IL 308020 A IL308020 A IL 308020A IL 30802023 A IL30802023 A IL 30802023A IL 308020 A IL308020 A IL 308020A
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- chemotherapeutics
- subject
- galectin
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182519P | 2021-04-30 | 2021-04-30 | |
| US202163193381P | 2021-05-26 | 2021-05-26 | |
| US202263313882P | 2022-02-25 | 2022-02-25 | |
| PCT/US2022/027142 WO2022232653A1 (en) | 2021-04-30 | 2022-04-29 | Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308020A true IL308020A (en) | 2023-12-01 |
Family
ID=83847357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308020A IL308020A (en) | 2021-04-30 | 2022-04-29 | Combination of anti-galectin-9 antibodies and chemotherapeutic agents for use in cancer treatment |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240182583A1 (https=) |
| EP (1) | EP4329808A4 (https=) |
| JP (1) | JP2024519449A (https=) |
| AU (1) | AU2022264597A1 (https=) |
| CA (1) | CA3217833A1 (https=) |
| IL (1) | IL308020A (https=) |
| WO (1) | WO2022232653A1 (https=) |
| ZA (1) | ZA202309774B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7581238B2 (ja) * | 2019-05-01 | 2024-11-12 | ニューヨーク・ユニバーシティ | 抗ガレクチン９抗体およびその使用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3080120C (en) * | 2017-10-27 | 2023-11-21 | New York University | Anti-galectin-9 antibodies and uses thereof |
| JP7581238B2 (ja) * | 2019-05-01 | 2024-11-12 | ニューヨーク・ユニバーシティ | 抗ガレクチン９抗体およびその使用 |
| US20220332832A1 (en) * | 2019-08-01 | 2022-10-20 | New York University | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics |
-
2022
- 2022-04-29 CA CA3217833A patent/CA3217833A1/en active Pending
- 2022-04-29 JP JP2023563934A patent/JP2024519449A/ja active Pending
- 2022-04-29 EP EP22796898.9A patent/EP4329808A4/en active Pending
- 2022-04-29 IL IL308020A patent/IL308020A/en unknown
- 2022-04-29 US US18/556,394 patent/US20240182583A1/en active Pending
- 2022-04-29 AU AU2022264597A patent/AU2022264597A1/en not_active Abandoned
- 2022-04-29 WO PCT/US2022/027142 patent/WO2022232653A1/en not_active Ceased
-
2023
- 2023-10-19 ZA ZA2023/09774A patent/ZA202309774B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240182583A1 (en) | 2024-06-06 |
| EP4329808A4 (en) | 2025-03-12 |
| ZA202309774B (en) | 2024-12-18 |
| EP4329808A1 (en) | 2024-03-06 |
| AU2022264597A9 (en) | 2023-11-16 |
| AU2022264597A1 (en) | 2023-11-09 |
| CA3217833A1 (en) | 2022-11-03 |
| WO2022232653A1 (en) | 2022-11-03 |
| JP2024519449A (ja) | 2024-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112473T1 (el) | Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα | |
| EA200101064A1 (ru) | Лечение раковых заболеваний путем комбинированного введения доцетаксела с рекомбинантными гуманизированными моноклональными анти-her2 антителами | |
| FI3548515T3 (fi) | Radioleimattuja anti-PD-L1-vasta-aineita immuno-PET-kuvantamiseen | |
| IL313952A (en) | Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment | |
| RU2018101314A (ru) | Комбинированные способы лечения антагонистами pd-l1 | |
| RU2016130056A (ru) | Способы лечения кожной инфекции путем введения антагониста il-4r | |
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| JP2021528423A5 (https=) | ||
| RU2012147340A (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR | |
| CY1113287T1 (el) | Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα | |
| JP2017533221A5 (https=) | ||
| WO2011101328A3 (en) | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor | |
| WO2020030977A3 (en) | Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors | |
| RU2013109172A (ru) | Сочетанная терапия афукозилированным антителом к cd20 с антителом к vegf | |
| ZA202406651B (en) | Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and chiauranib | |
| IL308020A (en) | Combination of anti-galectin-9 antibodies and chemotherapeutic agents for use in cancer treatment | |
| FI3630177T3 (fi) | Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle | |
| WO2021195557A3 (en) | Monoclonal antibodies targeting hsp70 and therapeutic uses thereof | |
| CA3242136A1 (en) | Clinical formulations of anti-tigit antibodies | |
| JP2022513029A5 (https=) | ||
| FI3880186T3 (fi) | PD-1-inhibiittoreiden intralesionaalinen antaminen ihosyövän hoitamiseksi | |
| DE60331827D1 (de) | Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren | |
| JP2020535180A5 (https=) | ||
| GEAP202416385A (en) | Methods for treating cancer with subcutaneous administration of anti-pd1 antibodies | |
| MX2023013614A (es) | Uso de conjugado farmaco-anticuerpo en combinacion con inhibidor de puntos de control inmunitario en el tratamiento del cancer urotelial. |